152 related articles for article (PubMed ID: 38345724)
1. Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors.
Ueki Y; Otsuka H; Otani T; Kasai R; Otomi Y; Ikemitsu D; Azane S; Kunikane Y; Bando T; Matsuda N; Okada Y; Takayama T; Harada M
Jpn J Radiol; 2024 May; 42(5):519-535. PubMed ID: 38345724
[TBL] [Abstract][Full Text] [Related]
2. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.
Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D
Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750
[TBL] [Abstract][Full Text] [Related]
3. Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors.
Kubota K; Okasaki M; Minamimoto R; Miyata Y; Morooka M; Nakajima K; Sato T
Ann Nucl Med; 2014 Dec; 28(10):1004-10. PubMed ID: 25179521
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors.
Stokkel MP; Rietbergen DD; Korse CM; Taal BG
Nucl Med Commun; 2011 Aug; 32(8):731-7. PubMed ID: 21633314
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942
[TBL] [Abstract][Full Text] [Related]
7. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
8.
Hope TA; Calais J; Zhang L; Dieckmann W; Millo C
J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
Kabasakal L; Demirci E; Ocak M; Decristoforo C; Araman A; Ozsoy Y; Uslu I; Kanmaz B
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
[TBL] [Abstract][Full Text] [Related]
10. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
[TBL] [Abstract][Full Text] [Related]
11. The influence of somatostatin receptor scintigraphy during preoperative staging of non-functioning pancreatic neuroendocrine tumours.
Jilesen AP; Hoefnagel SJ; Busch OR; Bennink RJ; Gouma DJ; Nieveen van Dijkum EJ
Clin Radiol; 2016 Jun; 71(6):537-42. PubMed ID: 27016111
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
13. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.
Krausz Y; Keidar Z; Kogan I; Even-Sapir E; Bar-Shalom R; Engel A; Rubinstein R; Sachs J; Bocher M; Agranovicz S; Chisin R; Israel O
Clin Endocrinol (Oxf); 2003 Nov; 59(5):565-73. PubMed ID: 14616879
[TBL] [Abstract][Full Text] [Related]
14. Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.
Shaverdian N; Pinchot SN; Zarebczan B; Gillis HC; Schiro A; Chen H
Ann Surg Oncol; 2013 Feb; 20(2):640-5. PubMed ID: 22941169
[TBL] [Abstract][Full Text] [Related]
15. Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms.
Ruf J; von Wedel F; Furth C; Denecke T; Stelter L; Steffen IG; Schütte K; Arend J; Ulrich G; Klose S; Bornschein J; Apostolova I; Amthauer H
J Nucl Med; 2016 Feb; 57(2):180-5. PubMed ID: 26609177
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
18. Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT.
Ruf J; Steffen I; Mehl S; Rosner C; Denecke T; Pape UF; Plotkin M; Amthauer H
Nucl Med Commun; 2007 Oct; 28(10):782-8. PubMed ID: 17728608
[TBL] [Abstract][Full Text] [Related]
19. 111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid.
Chiaravalloti A; Spanu A; Danieli R; Dore F; Piras B; Falchi A; Tavolozza M; Madeddu G; Schillaci O
Anticancer Res; 2015 Jul; 35(7):4265-70. PubMed ID: 26124388
[TBL] [Abstract][Full Text] [Related]
20. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]